| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0090-6980(02)00031-X |
| P698 | PubMed publication ID | 12432919 |
| P50 | author | Walter J Lukiw | Q92649708 |
| P2093 | author name string | Nicolas G Bazan | |
| Vittorio Colangelo | |||
| P2860 | cites work | Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease | Q22248076 |
| Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease | Q24316501 | ||
| Alzheimer's disease: genes, proteins, and therapy | Q28131806 | ||
| Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2 | Q28299729 | ||
| Phospholipases and phagocytosis: the role of phospholipid-derived second messengers in phagocytosis | Q28610270 | ||
| Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment | Q29547294 | ||
| Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein | Q29547803 | ||
| Cyclooxygenases 1 and 2 | Q29615645 | ||
| The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor | Q29618322 | ||
| Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5'-flanking regulatory sequences | Q31111891 | ||
| Cyclooxygenase-2 stimulates production of amyloid beta-peptide in neuroblastoma x glioma hybrid NG108-15 cells | Q31953588 | ||
| VAMP-1: a synaptic vesicle-associated integral membrane protein | Q33583102 | ||
| Inflammation of the brain in Alzheimer's disease: implications for therapy. | Q33594683 | ||
| Neurofilament functions in health and disease | Q33745290 | ||
| Regulation of platelet-activating factor (PAF) activity in human diseases by phospholipase A2 inhibitors, PAF acetylhydrolases, PAF receptor antagonists and free radical scavengers | Q33745976 | ||
| The biological and pathological function of presenilin proteins--simple cell systems and a worm in Alzheimer's disease research | Q33827602 | ||
| Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease | Q33835902 | ||
| Cellular and molecular basis of beta-amyloid precursor protein metabolism | Q33854048 | ||
| Molecular genetics of Alzheimer disease | Q33862540 | ||
| Suppression of synapsin II inhibits the formation and maintenance of synapses in hippocampal culture | Q33892828 | ||
| Impairment of axonal development and of synaptogenesis in hippocampal neurons of synapsin I-deficient mice | Q33893148 | ||
| Neuroinflammatory signaling upregulation in Alzheimer's disease | Q34074190 | ||
| Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. | Q34074245 | ||
| Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease | Q34263082 | ||
| Synergy by secretory phospholipase A2 and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. | Q48828436 | ||
| Cytoskeletal messenger RNA stability in human neocortex: studies in normal aging and in Alzheimer's disease. | Q48852765 | ||
| Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease. | Q48925866 | ||
| Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. | Q48987995 | ||
| Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. | Q52002767 | ||
| Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. | Q52020137 | ||
| Discordance and concordance of dementia of the Alzheimer type (DAT) in monozygotic twins indicate heritable and sporadic forms of Alzheimer's disease. | Q52048176 | ||
| Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. | Q52884779 | ||
| Dementia of the Alzheimer type: clinical and family study of 22 twin pairs. | Q53195030 | ||
| Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. | Q53203859 | ||
| Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. | Q53231397 | ||
| Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. | Q53236835 | ||
| Clinical trial of indomethacin in Alzheimer's disease. | Q53318286 | ||
| beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. | Q54447659 | ||
| Regulation of cyclooxygenase-2 expression in human mesangial cells - transcriptional inhibition by IL-13 | Q58869434 | ||
| Neurofilaments in health and disease | Q64869492 | ||
| Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation | Q70790738 | ||
| Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures | Q71082285 | ||
| Enhanced processing of APP induced by IL-1 beta can be reduced by indomethacin and nordihydroguaiaretic acid | Q72108160 | ||
| Effects of phospholipase A2 inhibitors on Ca2+ oscillations in pancreatic acinar cells | Q73343473 | ||
| COX-2 as a multifunctional neuronal modulator | Q73704223 | ||
| Interferon-gamma and interleukin 4 inhibit interleukin 1beta-induced delayed prostaglandin E(2)generation through suppression of cyclooxygenase-2 expression in human fibroblasts | Q73869344 | ||
| COX-1 and COX-2 in health and disease | Q87469049 | ||
| Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia | Q34312617 | ||
| Genomic structure and expression of STM2, the chromosome 1 familial Alzheimer disease gene | Q34383870 | ||
| Analysis of the 5' sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer disease | Q34419817 | ||
| Methodological variables in the assessment of beta amyloid neurotoxicity | Q35582072 | ||
| Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2 | Q35787852 | ||
| Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. | Q35969894 | ||
| Expression profiles of multiple genes in single neurons of Alzheimer's disease | Q36270250 | ||
| Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease | Q36415791 | ||
| Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity | Q36415795 | ||
| Aggregation State and Neurotoxic Properties of Alzheimer Beta-Amyloid Peptide | Q36686197 | ||
| Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. | Q36753784 | ||
| Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis | Q37083425 | ||
| COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex | Q37691478 | ||
| Arachidonic acid cascade and signal transduction | Q37815882 | ||
| Risk of Alzheimer's disease and duration of NSAID use. | Q39457609 | ||
| Neurofilament function and dysfunction: involvement in axonal growth and neuronal disease | Q40388310 | ||
| Synaptic vesicle proteins and regulated exocytosis. | Q40418217 | ||
| Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. | Q40820802 | ||
| Mediators of injury in neurotrauma: intracellular signal transduction and gene expression | Q40965329 | ||
| The effect of nitric oxide on cytokine-induced release of PGE2 by human cultured astroglial cells | Q41019496 | ||
| The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease | Q41036442 | ||
| Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies | Q41075378 | ||
| Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells. | Q41131861 | ||
| Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies | Q41619176 | ||
| Cyclooxygenases and the central nervous system | Q41646498 | ||
| Subcellular membrane impairment and application of phospholipase A2 inhibitors in endotoxic shock | Q41923779 | ||
| Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids | Q42506522 | ||
| Effects of protein kinase C activation on prostaglandin production and cyclooxygenase mRNA levels in ovine astroglia | Q42524729 | ||
| Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. | Q43638880 | ||
| Arachidonic acid and its metabolites in cerebral ischemia | Q44419491 | ||
| Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state | Q44689258 | ||
| A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors | Q46046983 | ||
| Transforming growth factor beta1 regulates the expression of cyclooxygenase in cultured cortical astrocytes and neurons. | Q47777972 | ||
| Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo | Q48114757 | ||
| Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs | Q48188389 | ||
| Expression of proteins linked to exocytosis and neurotransmission in patients with Creutzfeldt-Jakob disease | Q48200986 | ||
| Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles | Q48240552 | ||
| Identical twins discordant for presenile dementia of the Alzheimer type | Q48289623 | ||
| The neuromessenger platelet-activating factor in plasticity and neurodegeneration. | Q48290832 | ||
| Apolipoprotein E and Alzheimer's disease. The tip of the susceptibility iceberg | Q48293119 | ||
| Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains | Q48298397 | ||
| Synapsin I gene expression in the adult rat brain with comparative analysis of mRNA and protein in the hippocampus | Q48344995 | ||
| Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain | Q48394369 | ||
| Temporal cortex synaptophysin mRNA is reduced in Alzheimer's disease and is negatively correlated with the severity of dementia. | Q48461292 | ||
| Regional distribution of prostaglandin H synthase-2 and neuronal nitric oxide synthase in piglet brain. | Q48470743 | ||
| Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. | Q48480334 | ||
| Widespread peroxynitrite-mediated damage in Alzheimer's disease. | Q48728343 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 197-210 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Prostaglandins and Other Lipid Mediators | Q15754476 |
| P1476 | title | Prostaglandins and other lipid mediators in Alzheimer's disease | |
| P478 | volume | 68-69 |
| Q58797402 | A Selection of Important Genes and Their Correlated Behavior in Alzheimer's Disease |
| Q36718279 | A fast one-step extraction and UPLC-MS/MS analysis for E2/D 2 series prostaglandins and isoprostanes |
| Q34071942 | Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases |
| Q38293331 | Alteration in the activation state of new inflammation-associated targets by phospholipase A2-activating protein (PLAA) |
| Q35041190 | Alzheimer's disease and age-related memory decline (preclinical) |
| Q36216389 | Alzheimer's disease--a dysfunction in cholesterol and lipid metabolism |
| Q30499792 | Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models |
| Q36316280 | Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study |
| Q51018894 | Association between the characteristics of metabolic syndrome and Alzheimer's disease. |
| Q40169667 | Brain uptake and utilization of fatty acids, lipids and lipoproteins: application to neurological disorders |
| Q33806815 | Coordination of gene expression of arachidonic and docosahexaenoic acid cascade enzymes during human brain development and aging |
| Q48874383 | Cross-talk between human mesenchymal stem/progenitor cells (MSCs) and rat hippocampal slices in LPS-stimulated cocultures: the MSCs are activated to secrete prostaglandin E2. |
| Q40631665 | Cyclooxygenase (COX)-2 and COX-1 Potentiate β-Amyloid Peptide Generation through Mechanisms That Involve γ-Secretase Activity |
| Q34840113 | Cyclooxygenase-2 inhibitor blocks the production of West Nile virus-induced neuroinflammatory markers in astrocytes |
| Q42468434 | Cyclooxygenase-3 gene expression in Alzheimer hippocampus and in stressed human neural cells |
| Q53496008 | Effect of growth hormone on Cyclooxygenase-2 expression in the hippocampus of rats chronically exposed to ozone. |
| Q51487802 | Epigenetic Regulation of Cytosolic Phospholipase A2 in SH-SY5Y Human Neuroblastoma Cells. |
| Q47960190 | Exosomal biomarkers in Down syndrome and Alzheimer's disease |
| Q53262159 | Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling. |
| Q34735142 | Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. |
| Q36983897 | Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET. |
| Q35274780 | Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia |
| Q37736331 | Inflammatory, apoptotic, and survival gene signaling in Alzheimer's disease. A review on the bioactivity of neuroprotectin D1 and apoptosis |
| Q40343183 | Inhibition of cyclooxygenase as potential novel therapeutic strategy in N141I presenilin-2 familial Alzheimer's disease |
| Q35110642 | Inhibition of secreted phospholipase A2 by neuron survival and anti-inflammatory peptide CHEC-9 |
| Q37328073 | Intracellular- and extracellular-derived Ca(2+) influence phospholipase A(2)-mediated fatty acid release from brain phospholipids |
| Q35771195 | LC/MS/MS method for analysis of E₂ series prostaglandins and isoprostanes |
| Q61945887 | Lead (Pb) Exposure Enhances Expression of Factors Associated with Inflammation |
| Q92723269 | Lipid Metabolism in Late-Onset Alzheimer's Disease Differs from Patients Presenting with Other Dementia Phenotypes |
| Q47949218 | Membrane Aging as the Real Culprit of Alzheimer's Disease: Modification of a Hypothesis |
| Q59275594 | Metabolomic research on the role of interleukin-4 in Alzheimer’s disease |
| Q38073708 | MicroRNAs in the brain: it's regulatory role in neuroinflammation |
| Q33813237 | Microarray analysis on human neuroblastoma cells exposed to aluminum, β(1-42)-amyloid or the β(1-42)-amyloid aluminum complex |
| Q37060101 | Neurodegeneration and inflammation |
| Q41864750 | Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia. |
| Q90732202 | Novel Cellular Functions of Very Long Chain-Fatty Acids: Insight From ELOVL4 Mutations |
| Q39848491 | Novel piperazine derivative PMS1339 exhibits tri-functional properties and cognitive improvement in mice |
| Q41149645 | Oligomeric amyloid-beta induces MAPK-mediated activation of brain cytosolic and calcium-independent phospholipase A2 in a spatial-specific manner |
| Q35823015 | PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease. |
| Q37765687 | Phospholipase A2 and arachidonic acid in Alzheimer's disease |
| Q41921317 | Phospholipase A2-activating protein is associated with a novel form of leukoencephalopathy |
| Q46091324 | Plasma metabolic profile delineates roles for neurodegeneration, pro-inflammatory damage and mitochondrial dysfunction in the FMR1 premutation. |
| Q38132922 | Positive and negative effects of prostaglandins in Alzheimer's disease. |
| Q48143750 | Prostaglandin synthesis in rat brain astrocytes is under the control of the n-3 docosahexaenoic acid, released by group VIB calcium-independent phospholipase A2. |
| Q37141458 | Prostaglandin transporter expression in mouse brain during development and in response to hypoxia |
| Q44814173 | Prostaglandins are powerful inducers of NGF and BDNF production in mouse astrocyte cultures |
| Q39887324 | Protection of PMS777, a new AChE inhibitor with PAF antagonism, against amyloid-beta-induced neuronal apoptosis and neuroinflammation |
| Q30486807 | Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. |
| Q33689487 | Rat brain docosahexaenoic acid metabolism is not altered by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide |
| Q28567209 | Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2 |
| Q35883537 | Relation of blood cadmium, lead, and mercury levels to biomarkers of lipid peroxidation in premenopausal women |
| Q27012569 | Role of redox signaling in neuroinflammation and neurodegenerative diseases |
| Q35070143 | Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis |
| Q37701322 | Targeting NADPH oxidase and phospholipases A2 in Alzheimer's disease |
| Q37054938 | The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease |
| Q36806227 | The fatty acid oxidation product 15-A3t-isoprostane is a potent inhibitor of NFκB transcription and macrophage transformation |
| Q28256707 | The onset of brain injury and neurodegeneration triggers the synthesis of docosanoid neuroprotective signaling |
| Q36003895 | The role of group I metabotropic glutamate receptors in neuronal excitotoxicity in Alzheimer's disease |
| Q53356993 | Using direct infusion mass spectrometry for serum metabolomics in Alzheimer's disease. |
Search more.